The relationship between thrombocytopenia and immune thrombocytopenia

There is a close relationship between thrombocytopenia and immune thrombocytopenia. Immune thrombocytopenia (ITP) is a type of thrombocytopenia, which specifically refers to a disease caused by increased destruction or insufficient production of platelets caused by immune factors, resulting in a decrease in the number of platelets in the blood.

The mechanism of immune thrombocytopenia involves abnormalities in the body's immune system. Under normal circumstances, the immune system is responsible for identifying and eliminating foreign pathogens. However, in people with immune thrombocytopenia, the immune system mistakenly sees platelets as foreign material and produces antibodies against them. After these antibodies bind to platelets, they will be destroyed by the phagocytic system of organs such as the spleen, resulting in a decrease in the number of platelets. In addition, immune thrombocytopenia may also be related to factors such as abnormal T cells and the body's immune response to platelet-related antigens.

The clinical manifestations of immune thrombocytopenia are closely related to the degree of thrombocytopenia. Mild patients may have no obvious symptoms, while severe patients may experience bleeding symptoms such as skin petechiae, ecchymoses, nosebleeds, and gum bleeding, and may even suffer from serious conditions such as internal bleeding.

In terms of diagnosis, immune thrombocytopenia requires a blood test to determine the number of platelets, and may require further testing such as a bone marrow biopsy and immune antibody testing to determine whether an autoimmune problem is present. In the treatment of immune thrombocytopenia, doctors may use steroids, immune globulin, drugs that promote platelet production[Eltrombopag/Eltrombopag and Avatrombopag/Avatrombopag] and other drugs to suppress the abnormal response of the immune system, thereby protecting platelets and promoting their production.